Evidence map›Paper›PMID 38653511›Full record

ArticleBMJ open2024

Web-based cognitive rehabilitation intervention for cancer-related cognitive impairment following chemotherapy for aggressive lymphoma: protocol for a randomised pilot trial.

Priscilla Gates, Heather J Green, Karla Gough, Haryana Dhillon, Janette L Vardy, Michael Dickinson, Jade Guarnera, Meinir Krishnasamy, Patricia M Livingston, Victoria White and 2 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Priscilla GatesCognitive Neuroscience Unit, Deakin University, Burwood, Victoria, Australia priscilla.gates@deakin.edu.au.ORCID 0000-0002-7978-5802
Heather J GreenFaculty of Health, Griffith University, Gold Coast, Queensland, Australia.
Karla GoughHealth Services Research, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
Haryana DhillonFaculty of Science, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-4039-5169
Janette L VardySydney Medical School, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-5739-5790
Michael DickinsonClinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Jade GuarneraCognitive Neuroscience Unit, Deakin University, Burwood, Victoria, Australia.
Meinir KrishnasamyHealth Services Research, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia.
Patricia M LivingstonFaculty of Health, Deakin University, Burwood, Victoria, Australia.ORCID 0000-0001-6616-3839
Victoria WhiteFaculty of Health, Deakin University, Burwood, Victoria, Australia.ORCID 0000-0001-6619-8484
Anna UgaldeFaculty of Health, Deakin University, Burwood, Victoria, Australia.ORCID 0000-0002-2473-8435
Karen CaeyenberghsCognitive Neuroscience Unit, Deakin University, Burwood, Victoria, Australia.
Deakin University · AUThe University of Melbourne · AUThe University of Sydney · AUGriffith University · AUPeter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCancer-related cognitive impairment is common among people diagnosed with and treated for cancer. This can be a distressing and disabling side effect for impacted individuals. Interventions to mitigate cognitive dysfunction are available, but, to date, most have been trialled in samples that are largely or exclusively composed of people with solid tumours. Intervention strategies to support cognitive functioning are needed, but there is a paucity of research in this area. The main aim of this study is to test the feasibility and acceptability of methods and procedures intended for use in a definitive trial of a web-based cognitive rehabilitation programme, Responding to Cognitive Concerns (eReCog), in people who have received chemotherapy for aggressive lymphoma. METHODS AND ANALYSIS: The proposed study is a single-site, parallel-group, pilot randomised controlled trial, with one baseline and one follow-up (or postintervention) assessment. 38 people from the target population with low perceived cognitive function based on the Cognitive Change Screen will be recruited from a specialist cancer centre between July 2023 and June 2024. After baseline assessment, participants will be randomised one-to-one to receive usual care only (a factsheet about changes in memory and thinking for people with cancer) or eReCog plus usual care. The 4-week eReCog intervention consists of four online modules offering psychoeducation on cognitive impairment associated with cancer and its treatment, skills training for improving memory, and attention and relaxation training. Study outcomes will include the feasibility of recruitment and retention at follow-up assessment (primary outcomes), as well as adherence to, usability of and intrinsic motivation to engage with eReCog, and compliance with study measures. The potential efficacy of eReCog will also be evaluated. ETHICS AND DISSEMINATION: Ethical approval was granted by the Peter MacCallum Cancer Centre Human Research Ethics Committee in Victoria, Australia (HREC/97384/PMCC). Study findings will be disseminated via peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry, ACTRN12623000705684.

Indexed as

Chemotherapy-Related Cognitive ImpairmentInternet-Based InterventionLymphomaCognitive Behavioral TherapyCognitive TrainingFeasibility StudiesHumansInternetPilot ProjectsRandomized Controlled Trials as TopicLymphomaRandomized Controlled TrialSocial Cognition

Identifiers

PMID38653511
PMCPMC11043699
OpenAlexW4395052227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.